HINGHAM, Mass., October 06, 2021 (GLOBE NEWSWIRE) – Microbot Medical Inc. (Nasdaq: MBOT), has announced that the United States Patent and Commerce Office (USPTO) has issued a notice of clearance covering the company LIBERTY® Robotic System. Globally, the company now has 45 issued / authorized patents and 24 pending patent applications.

“This achievement is another important step that adds a solid foundation for building our sustainable competitive advantage. This intellectual property allows us to protect our assets globally and move towards commercialization, ”commented Harel Gadot, CEO, Chairman and Chairman of the Board. “We believe our new technology is uniquely positioned to transform catheter-based procedures and benefit more patients worldwide while protecting physicians from radiation and reducing physical fatigue. “

The authorized patent relates to a device for automatically inserting and manipulating a medical tool into and within a body lumen. The permitted claims cover a compact robotic drive for driving and manipulating the motion of at least one elongated surgical tool, the robotic drive comprises a housing including motors and a first motor driven tool movement member positioned and configured. to advance or retract the elongated surgical tool, and a second motor driven tool displacement member configured to roll the elongated surgical tool about the long axis.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a preclinical medical device company specializing in transformational micro-robotic technologies, focusing primarily on the natural and artificial lights of the human body. Microbot’s current proprietary technology platforms form the basis for the development of a Multi-Generation Pipeline (MGPP) portfolio.

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham and Yossi Bornstein with the aim of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. More information about Microbot Medical is available at http://www.microbotmedical.com.

Safe harbor

Statements relating to the recorded direct offering, timing, amount and intended use of the products and statements relating to future financial and / or operating results, future growth of research, technology, development clinical and potential opportunities for Microbot Medical Inc. and its subsidiaries, as well as other statements concerning the expectations, beliefs, objectives, plans or future prospects expressed by the management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and federal securities laws. All statements which are not historical facts (including, but not limited to, statements which contain words such as “will”, “believes”, “plans”, “anticipates”, “expects” And “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and / or commercialization of potential products, including LIBERTY and SCS, the result of its studies to assess LIBERTY, SCS and other existing and future technologies, uncertainty in the results of preclinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to raise future capital and maintain intellectual property rights. Additional information on the risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the website of the SEC at www.sec.gov. Microbot Medical disclaims any intention or obligation to update these forward-looking statements, except as required by law.

Investor contact:

Michael Polyviou EVC Group [email protected] 732-933-2754

Copyright 2021 GlobeNewswire, Inc.


Source link

Leave a Reply

Your email address will not be published.